Eli Lil­ly has an­ted up for its next big bet on a next-gen pain drug, buy­ing Hy­dra as­sets

With its new CGRP mi­graine drug Em­gal­i­ty (gal­canezum­ab) OK’d a few months ago and more late-stage work un­der­way on las­mid­i­tan and

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland